We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors
News

Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors

Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors
News

Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors

A robust multiplex mass spectrometric assay for screening small-molecule inhibitors of CD73 with diverse inhibition modalities. Credit: Gejing Deng
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.

The methodology described by authors Gejing Deng (Sanofi) et al., uses multiple stable isotope-labeled substrates for carrying out CD73 reactions followed by sample pooling then simultaneously quantifying multiple reaction products using ultra-fast RapidFire-MS/MS.

In contrast to other optical based methodologies, this methodology allows identifying molecules with diverse inhibition modalities and characterizing inhibitors using both recombinant CD73 and CD73+ cells.

This article has been republished from materials provided by SLAS. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement